Moran Eye Center, University of Utah
Salt Lake City, Utah, 84132, United States
Completed
NCT Number: NCT00420602
DHA Supplementation in Patients With STGD3
We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, the purpose of this study is to follow STGD3 patients as they supplement their diets with DHA/EPA.
Completed
Looking for future studies?
Notify MeKey information
Age range
18 year–105 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- All Moran Eye Center patients with STGD3
Exclusion criteria
- All others
Treatment and study plan
Over the counter DHA/EPA dietary supplementation
Dietary Supplement1000 mg/day DHA/EPA
Primary outcomes
-
ERG
Time frame: 1 year
Secondary outcomes
-
Visual acuity
Time frame: 1 year
Sponsors and collaborators
Lead sponsor
University of Utah
Other
Registry information
Official study title
Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3
Important dates
- Study start
- 2007
- Primary completion
- 2017
- Study completion
- 2017
- First posted
- Jan 11, 2007
- Registry last updated
- May 9, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.